Biomarkers for CNV and response to anti-VEGF in eye disease
Official title: Biomarkers Analysis of Mineralocortoid Receptor Activation in the Serum and Ocular Fluid of Patients With Choroidal Neovascularization
Run by Institut National de la Santé Et de la Recherche Médicale, France · NCT04439708 · Data updated 2026-11-12
This study tests blood and eye fluid biomarkers to see if they predict how people with type 1 choroidal neovascularization respond to anti-VEGF therapy.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 90 Years |
| Sex | All |
| Enrollment | 250 (estimated) |
| Sponsor | Institut National de la Santé Et de la Recherche Médicale, France Government |
| Locations | 2 sites (Paris and 1 other locations) |
| Status | Recruiting |
| Started | July 6, 2020 |
| Main results expected | January 6, 2027 |
| Study ends | July 6, 2027 |
| Registry record updated | July 7, 2026 |
| Trial ID | NCT04439708 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults with type 1 CNV associated with AMD or central serous chorioretinopathy, not having intravitreal injections in the prior 3 months, and who can consent.
✕Probably not a fit
Patients without CNV or those with recent intravitreal injections, or those lacking consent, may not derive biomarker-based benefits from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study investigates whether concentrations of metabolites from the mineralocorticoid receptor pathway in blood and aqueous humor are associated with CNV presence and response to anti-VEGF treatment. Participants include patients with type 1 CNV linked to central serous chorioretinopathy or age-related macular degeneration, compared with controls without CNV. Researchers will compare biomarker levels between groups and relate them to treatment response, aiming to understand CNV pathogenesis and identify predictive biomarkers. The study builds on emerging evidence that the mineralocorticoid pathway may contribute to CNV formation. No interventional treatment is performed beyond standard anti-VEGF management in the broader clinical context.
Why it matters
Potential benefit: Identifying biomarkers could help predict which patients will respond to anti-VEGF therapy and guide personalized treatment decisions.
How similar studies have gone: Previous research has suggested mineralocorticoid pathways may relate to CNV, but direct biomarker correlations with anti-VEGF response are still emerging and exploratory.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Patients of group 1: * Patients with type 1 choroidal neovascularization in a context of central serous chorioretinoathy or age related macular degeneration * Patients without intravitreal injection or last intravitreal injection \> 3 months * Informed signed consent Patients of group 2: * Patients without choroidal neovascularization * Patients with intraocular surgery (cataract or vitrectomy surgery) * Signed consent Exclusion Criteria: * Myocardial infarction \< 12 months * Chronic renal failure * Inflammatory disease * Infectious disease :HIV, viral hepatitis, tuberculosis * Type 1 or 2 Diabetes * Patients treated by mineralocorticoid antagonist treatment. * Type 2 or 3 choroidal neovascularization * Pregnant woman
Where it's running
-
Ophtalmopole Hôpital Cochin
Paris, France Recruiting -
Hôpital Foch
Suresnes, France Recruiting
Study contacts
- Study coordinator: Francine Behar-Cohen, Dr
- Email: francine.cohen@aphp.fr
- Phone: 01 44 27 81 64
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Tiespectus (MK-8748) versus aflibercept to treat neovascular (wet) age-related macular degeneration
The study will see if tiespectus (MK-8748) works as well as aflibercept for people with newly diagnosed neovascular (wet) age-related macular degeneration.
-
Comparing tiespectus (MK-8748) with aflibercept for wet age-related macular degeneration
This study will test whether tiespectus (MK-8748) works as well as aflibercept for people with newly diagnosed neovascular (wet) age-related macular degeneration.
-
Watching a short video before anti-VEGF eye injections
This trial will test whether watching a brief procedural video before a first anti-VEGF intravitreal injection helps people with retinal diseases feel less anxious and have fewer or smaller subconjunctival hemorrhages.
-
Dynamic hormone profiling for diagnosing primary aldosteronism
This study is testing a new way to measure hormone levels in people who might have primary aldosteronism to see if it can help diagnose the condition more easily and accurately.
-
Quarterly faricimab maintenance for neovascular age-related macular degeneration
This test will see if faricimab injections every 12–16 weeks can keep neovascular age-related macular degeneration stable after 2–4 initial loading doses.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.